BioSpace News Archive

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Sylvester “Sly” Steele to the newly created position of Vice President and General Manager of the Government Channels Business Unit. Mr. Steele brings to electroCore extensive leadership experience, including more than 20 years in the U.S. Navy leading organizations and developing complex systems. In his role, Mr. Steele

VolitionRx Limited a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, hosted a capital markets day event yesterday and releases a video of that event.

Curis, Inc. highlighted a paper published online in ACS Medicinal Chemistry Letters, a peer-reviewed publication of the American Chemical Society, titled, “Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies.” The paper describes the preclinical work done to select CA-4948 and its on-target engagement and inhibition of IRAK4 in various animal studies.

AppliedVR, a pioneer advancing the next generation of digital medicine, today announced its EaseVRx product received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for treating treatment-resistant fibromyalgia and chronic intractable lower back pain.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it is presenting three posters on its late-stage, novel broad-spectrum antifungal, ibrexafungerp, at IDWeek 2020.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, October 27, 2020 at 5pm ET to discuss third quarter 2020 financial results and provide a corporate update.

This is the company’s 6th FDA clearance and further solidifies its leadership as the most comprehensive acute AI vendor in the market

CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q3 2020 financial results after the market close on Wednesday, November 4, 2020.

MyBiotics Pharma Ltd., a microbiome therapeutics company, announced today that it was awarded 2.0 million Euros ($2.3 million) by the European Union as part of its Horizon 2020 Program.

FSD Pharma Inc. (Nasdaq: HUGE) (“FSD Pharma” or the “Company”), today announced the closing of previously announced definitive agreements with investors for the purchase and sale of 4,318,179 Class B Subordinate Voting Shares of the Company (“Shares”) and warrants to purchase 3,454,543 Shares (collectively, the “Securities”) at a purchase price of US$2.20 per Share in a registered direct offering